Dosing

General dosing and administration information1

Image of TOFIDENCE
Image of TOFIDENCE
Image of TOFIDENCE

Not actual size.

For RA, PJIA, and SJIA, TOFIDENCE may be used alone or in combination with methotrexate, and in RA, other DMARDs may be used. Avoid using TOFIDENCE with biological DMARDs.

For GCA, TOFIDENCE can be used alone following discontinuation of glucocorticoids.

Obtain and assess baseline complete blood count (CBC) and liver function tests prior to treatment.

  • Laboratory monitoring is recommended due to potential consequences of treatment-related laboratory changes in neutrophils, platelets, lipids, and liver function tests. Dosage modifications may be required.  

TOFIDENCE is administered as a 60-minute single intravenous drip infusion. Do not administer as an intravenous push or bolus.

RA, GCA, PJIA, and SJIA—It is recommended that TOFIDENCE not be initiated in patients with an ANC below 2000 per mm3, platelet count below 100,000 per mm3, or who have ALT or AST above 1.5 times the ULN.

COVID-19—It is recommended that TOFIDENCE not be initiated in patients with an ANC below 1000 per mm3, platelet count below 50,000 mm3, or ALT or AST above 10 times ULN.

For patients with RA or COVID-19, TOFIDENCE doses exceeding 800 mg/infusion are not recommended.

For patients with GCA, TOFIDENCE doses exceeding 600 mg/infusion are not recommended.

For patients with RA, GCA, COVID-19, and PJIA and SJIA patients at or above 30 kg, dilute to 100 mL in 0.9% Sodium Chloride Injection, USP for intravenous infusion using aseptic technique.

For PJIA and SJIA patients less than 30 kg, dilute to 50 mL in 0.9% Sodium Chloride Injection, USP for intravenous infusion using aseptic technique.

Hold TOFIDENCE treatment if a patient develops a serious infection until the infection is controlled.

Dose modifications are recommended for management of certain dose-related laboratory changes including elevated liver enzymes, neutropenia, and thrombocytopenia. Interruption of dosing may be needed.

Indication1 Dosage1 Dosing Schedule1
Moderately to severely active RA in adult patients with inadequate response to one or more DMARDs Starting at 4 mg/kg followed by an increase to 8 mg/kg based on clinical response* Every 4 weeks
GCA
Adult patients
6 mg/kg Every 4 weeks, in combination with a tapering course of glucocorticoids
PJIA (active)
Patients 2 years of age or older
Patients weighing
<30 kg: 10 mg/kg
Every 4 weeks
Patients weighing
≥30 kg: 8 mg/kg
Every 4 weeks
SJIA (active)
Patients 2 years of age or older
Patients weighing
<30 kg: 12 mg/kg
Every 2 weeks
Patients weighing
≥30 kg: 8 mg/kg
Every 2 weeks
Hospitalized adult patients with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO
8 mg/kg Single dose, one additional dose after 8 hours if needed

 

*When used in combination with DMARDs or as monotherapy.
†TOFIDENCE can be used alone following discontinuation of glucocorticoids.
‡If clinical signs or symptoms worsen or do not improve after the first dose, one additional infusion of TOFIDENCE may be administered at least 8 hours after the initial infusion.

ALT=alanine aminotransferase; ANC=absolute neutrophil count; AST=aspartate aminotransferase; COVID-19=coronavirus disease 2019; DMARD=disease-modifying anti-rheumatic drug; ECMO=extracorporeal membrane oxygenation; GCA=giant cell arteritis; PJIA=polyarticular juvenile idiopathic arthritis; RA=rheumatoid arthritis; SJIA=systemic juvenile idiopathic arthritis; ULN=upper limit of normal

 

Help start a movement for more patients

You also might be interested in:
Reference
  1. TOFIDENCE Prescribing Information, Cambridge, MA: Biogen.